Featured Research

from universities, journals, and other organizations

Lyme disease vaccine shows promise in clinical trial

Date:
May 10, 2013
Source:
Stony Brook Medicine
Summary:
The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine revealed it to be promising and well tolerated. The vaccine was shown to produce substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States.

The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at Baxter International Inc., a U.S. based healthcare company, revealed it to be promising and well tolerated, according to a research paper published online in The Lancet Infectious Diseases. The vaccine was shown to produce substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States. Baxter International conducted the clinical trial of the vaccine.

Since the early 1990s, Benjamin Luft, MD, the Edmund D. Pellegrino Professor of Medicine at Stony Brook University School of Medicine, and the late John Dunn, Ph.D., a biologist at Brookhaven National Laboratory, spearheaded the initial development of the original vaccine antigen concept, and together with researchers at Baxter International helped bioengineer the formulation used in the clinical trial. Through the Stony Brook University School of Medicine and Brookhaven National Laboratory, The Research Foundation of the State of New York licensed intellectual property of the Lyme vaccine technology to Baxter International. Baxter International researchers in collaboration with Luft and Dunn developed further innovations employed in the Lyme vaccine used in the clinical trial.

In the article, "Safety and immunogenicity of a novel multivariant OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomized, dose-escalation phase 1/2 trial," Principal Investigator P. Noel Barrett, PhD, of Baxter, Biomedical Research Centre, and co-authors evaluated the safety and immunogenicity of the vaccine in a range of doses in 300 people living in Austria and Germany. Study participants received three primary immunizations and one booster immunization. All doses and formulations, some of which included an adjuvant, an additive to stimulate immune response to the vaccine, induced substantial antibody titers against all species of Borrelia. The vaccine demonstrated predominantly mild adverse reactions and no-vaccine related serious events occurred in the sample population.

"The results of the clinical trial conducted by Baxter are promising because the vaccine generated a potent human immune reaction, covered the complete range of Borrelia active in the entire Northern hemisphere, and produced no major side effects," said Dr. Luft, a co-author on the paper. "We hope that a larger-scale, Phase 3 trial will demonstrate not only a strong immune response but true efficacy in a large population that illustrates protection against Lyme disease."

Dr. Luft said that for years, one of the main challenges of developing a Lyme disease vaccine was to discover a method that could produce a vaccine effective on all Borrelia species. With the aid of technologies and expertise at Stony Brook and Brookhaven, Drs. Luft and Dunn focused vaccine development on the most abundant Borrelia outer surface protein found when the spirochete bacteria reside in ticks, which commonly transmit the disease. Using the scaffold of this protein, called OspA, they, in collaboration with researchers at Baxter, bioengineered a set of unique OspA proteins not found in nature. These new OspAs share different parts from different species of Borrelia. The new proteins are called chimeras.

"After a series of experimentations and refinements, formulations consisting of these new OspA proteins were shown to protect against a broad spectrum of Lyme disease spirochetes," said Dr. Luft, summarizing the research results.

The vaccine used in the European clinical trial is based on these newly created OspA proteins and is therefore designed for broad based coverage.


Story Source:

The above story is based on materials provided by Stony Brook Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Nina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, Daniel Portsmouth, Alexandra Löw-Baselli, Sandor Fritsch, Ian Livey, Brian A Crowe, Michael Schwendinger, Peter Brühl, Andreas Pilz, Thomas Dvorak, Julia Singer, Clair Firth, Benjamin Luft, Bernhard Schmitt, Markus Zeitlinger, Markus Müller, Herwig Kollaritsch, Maria Paulke-Korinek, Meral Esen, Peter G Kremsner, Hartmut J Ehrlich, P Noel Barrett. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. The Lancet Infectious Diseases, 2013; DOI: 10.1016/S1473-3099(13)70110-5

Cite This Page:

Stony Brook Medicine. "Lyme disease vaccine shows promise in clinical trial." ScienceDaily. ScienceDaily, 10 May 2013. <www.sciencedaily.com/releases/2013/05/130510075337.htm>.
Stony Brook Medicine. (2013, May 10). Lyme disease vaccine shows promise in clinical trial. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2013/05/130510075337.htm
Stony Brook Medicine. "Lyme disease vaccine shows promise in clinical trial." ScienceDaily. www.sciencedaily.com/releases/2013/05/130510075337.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) — A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) — Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) — New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins